Extralevator abdominoperineal excision with transpelvic levator dissection: a report of 36 cases.
- Author:
Zhifen CHEN
1
;
Pan CHI
;
Guoxian GUAN
;
Huiming LIN
;
Xingrong LU
;
Ying HUANG
;
Xing LIU
;
Weizhong JIANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Digestive System Surgical Procedures; methods; Female; Humans; Male; Middle Aged; Pelvic Floor; Perineum; surgery; Rectal Neoplasms; surgery; Rectum; surgery
- From: Chinese Journal of Gastrointestinal Surgery 2014;17(1):60-64
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the safety, feasibility, perioperational information and post-operational pathology of the modified abdominal operation of extralevator abdominoperineal excision (ELAPE), meaning transpelvic levator dissection under direct visualization.
METHODSFrom January 2010 to March 2013, 36 patients with rectal tumors(≤5 cm distance to anal verge) underwent extralevator abdominoperineal excision with transpelvic levator dissection by laparoscopic or open surgery, without position change during the perineal operation. The preliminary result of this modified technique was summarized.
RESULTSThe levator ani muscles of all the patients were successfully dissected with transpelvic levator dissection and the extent of levator dissection was determined individually according to its involvement. No position was changed during the perineal operation. No conversion to open approach in laparoscopic surgery group was observed, and only 1 case of rectum perforation occurred in open surgery group. The mean operation time was (220.9±36.8) min, and mean intraoperative blood loss was(121.6±99.7) ml. All the specimens had levator ani muscles attached to the mesorectum and positive rate of circumferential resection margin was 5.6%(2/36).
CONCLUSIONSTranspelvic levator dissection simplifies the procedure of ELAPE and achieves individualized dissection of levator. This technique is effective without position change during perineal operation, with shorter operation time and acceptable oncologic outcomes.